-
-
-
-
-
-
-
Revolution Medicines (RVMD) call put ratio 3.3 calls to 1 put after presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO
-
-
-
-
-
-
-
Revolution (RVMD) PT Lowered to $183 at Needham
-
-
-
-
-
-
-
Revolution Medicines closes $2.2 billion dual public offerings
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $147 at Leerink Partners
-
-
-
-
-
-
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
-
-
-
-
-
-
Revolution Medicines (RVMD) spreader of April 80, June 50 and June 80 puts
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $160 at Guggenheim
-
423,329 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

